Related Experiment Video
Updated: Oct 5, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Multi-Vessel Disease in Metabolically Healthy Obese Patients Presenting with ST-Elevation Myocardial Infarction
Zach Rozenbaum1, Ilan Merdler1, Itamar Lowenstein1
1Department of Cardiology, Tel Aviv Sourasky Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Insights
Metabolically healthy obese patients with ST-elevation myocardial infarction (STEMI) had less multi-vessel coronary artery disease. This obesity paradox did not increase mortality risk, despite higher triglycerides.
Area of Science:
- Cardiology
- Metabolic Health
- Obesity Research
Background:
- Obesity's role in coronary artery disease (CAD) is unclear due to confounding comorbidities.
- Understanding obesity as an isolated CAD risk factor is crucial.
Purpose of the Study:
- To investigate the association between obesity and extensive CAD in metabolically healthy ST-elevation myocardial infarction (STEMI) patients.
- To explore patient outcomes based on Body Mass Index (BMI).
Main Methods:
- Stratified STEMI patients with a metabolically healthy phenotype by BMI: lean (18.5-25 kg/m²), overweight (25.01-30 kg/m²), and obese (>30 kg/m²).
- Analyzed rates of multi-vessel disease and mortality.
Main Results:
- Obese patients had lower rates of multi-vessel disease (12.9%) compared to overweight (22.9%) and lean (28%) patients.
- Obesity was independently associated with reduced likelihood of multi-vessel disease (OR 0.4, P=0.029).
- No significant differences in 30-day or long-term mortality were observed across BMI groups.
Conclusions:
- Metabolically healthy obesity is linked to less multi-vessel coronary artery disease in STEMI patients.
- This association persists despite elevated triglycerides and does not lead to increased mortality.
Background:
The extent and impact of obesity as an isolated risk factor for coronary artery disease is not clear since co-morbidities serve as confounders and may mask this association.
Objectives:
To examine whether obesity is associated with extensive coronary artery disease among metabolically healthy patients presenting with ST-elevation myocardial infarction (STEMI) and to explore the outcomes according to body mass index (BMI).
Methods:
We stratified STEMI patients who had a metabolically healthy phenotype and available weight and height data according to BMI: 18.5-25 kg/m² (lean), 25.01-30 kg/m² (overweight), and > 30 kg/m² (obese).
Results:
Overall 381 patients were included, 42% lean, 41% overweight, and 17% obese. Patients with increased BMIs had higher levels of low-density proteins and triglycerides (P < 0.05). Obese patients presented with the lowest rates of multi-vessel disease (12.9% vs. 22.9% for overweight and 28% for lean). In a univariable analysis, obese patients were 60% less likely to be diagnosed with multi-vessel disease (odds ratio 0.4, 95% confidence interval 0.2-0.9, P = 0.021) compared to lean patients. The association remained significant in a multivariable model adjusted for baseline characteristics (P = 0.029). There were no differences in 30-day or long-term mortality (median follow-up 3.2 years) among the groups (P > 0.1 for all comparisons).
Conclusions:
Metabolically healthy phenotype obesity was associated with lower rates of multi-vessel disease despite higher levels of triglycerides. However, this association did not translate into increased mortality.
More Related Videos
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

